The immunobiology of CD4+ CD25+ T regulatory cells
The immunobiology of CD4+ CD25+ T regulatory cells
批准号:
8769997
负责人:
Thomas R Malek
金额:
$38.25万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-12-01 至 2016-11-30
关键词:
AddressAffinityAgreementAllogenicAntigensAreaAutoantigensAutoimmune DiseasesAutoimmunityBiological ModelsBiological Response ModifiersBone MarrowCeliac DiseaseCellsClinicalClinical TrialsDataDrug usageEnsureEtiologyExcisionGenetic PolymorphismGraft RejectionGrantHealthHematopoietic Stem Cell TransplantationHematopoietic stem cellsHumanIL2RA geneImmuneImmune ToleranceImmune responseImmune systemImmunityImmunobiologyImmunosuppressionImmunotherapyInfectionInsulin-Dependent Diabetes MellitusInterleukin-2KnowledgeLaboratoriesLinkModelingMultiple SclerosisMusMutationPeptide/MHC ComplexPeripheralPopulationPredispositionProductionReactionRegulatory T-LymphocyteReportingResearch DesignResistanceRheumatoid ArthritisSelf ToleranceSpecificityStem cell transplantSuppressor-Effector T-LymphocytesT-LymphocyteTestingTherapeuticTissuesWorkautoreactive T cellbasechemotherapyclinically relevantconditioninggenetic risk factorimprintin vivo Modelinterestmouse modelnovelpreventreconstitutionresponsesystemic autoimmune diseasetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): There is considerable interest in understanding the basic immunobiology of T regulatory (Treg) cells as they offer a means to inhibit unwanted immune responses that occur during autoimmune disease or as a consequence of hematopoietic stem cell transplantation (HSCT) or tissue transplant rejection reactions. An important area of Treg cell immunobiology that is poorly understood concerns the antigen specificity of these suppressor T cells in maintaining peripheral self-tolerance. We have developed in vivo model systems that permits direct examination of TCR diversity and specificity as it relates to control of autoimmune disease. In one model, Treg cells are adoptively transferred into IL-2Rb-/- mice, which develop rapid lethal systemic autoimmunity due to their failed production of effective Treg cells. These donor Treg cells fully prevent this autoimmunity and provide a defined population of therapeutic Treg cells to examine issues regarding TCR diversity and specificity. In another clinically relevant model, host Treg cells that survive lethal conditioning after HSCT function to suppress autoreactive donor-derived T cells. We have used these models to address questions concerning the importance of high TCR diversity of Treg cells for self-tolerance. Our initial work shows that in settings of rampant breakdown of immune tolerance, control of autoimmunity is achieved by only a fraction of the available Treg TCR repertoire that was accompanied by substantial peripheral reshaping. Ultimately, too severe constraints on Treg TCR diversity sometimes resulted in autoimmunity. This latter finding is consistent with the hypothesis that TCR repertoire skewing represents a potential intrinsic Treg cell deficit that causes autoimmunity. This proposal plans to build on these data and to exploit the unique features of these models to more precisely define the requirements for Treg TCR diversity and specificity in control of autoimmunity. An important related objective is to investigate mechanisms operative that contribute to peripheral modulation of Treg specificities. To address these issues we propose the following specific aims:1) To further characterize the relevance of TCR diversity in Foxp3+ regulatory T cells by evaluating the efficacy and durability of Treg cells with limited diversity to suppress autoimmunity; 2) to test the requirement for homeostatic mechanisms to drive peripheral reshaping of the Treg TCR repertoire; and 3) to evaluate the effect of altering TCR selection of Treg and autoreactive T cells on peripheral self-tolerance and Treg TCR repertoire reshaping. Completion of these aims should expand our knowledge concerning the selection and diversity of the Treg TCR as it directly relates to the mechanisms by which these cells maintain self-tolerance. This proposal has the potential to impact the field by providing new and essential information that is likely critical for application of Treg cells in immunotherapy to the multitude of scenarios where one wish to inhibit unwanted immune responses.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.4049/jimmunol.1500595
发表时间:
2016-05-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Toomer KH, Yuan X, Yang J, Dee MJ, Yu A, Malek TR]
通讯作者:
Malek TR
IL-2Rβ-dependent signaling and CD103 functionally cooperate to maintain tolerance in the gut mucosa.
DOI:
10.4049/jimmunol.1400955
发表时间:
2015-02-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Yuan X, Dee MJ, Altman NH, Malek TR]
通讯作者:
Malek TR
DOI:
10.1111/imr.12163
发表时间:
2014-05
期刊:
Immunological reviews
影响因子:
8.7
作者:
[Yuan X, Cheng G, Malek TR]
通讯作者:
Malek TR
DOI:
10.4049/jimmunol.0902379
发表时间:
2010-01-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Adeegbe D, Matsutani T, Yang J, Altman NH, Malek TR]
通讯作者:
Malek TR
DOI:
10.1007/s12026-013-8452-5
发表时间:
2013-12
期刊:
IMMUNOLOGIC RESEARCH
影响因子:
4.4
作者:
[Bayer, Allison L., Pugliese, Alberto, Malek, Thomas R.]
通讯作者:
Malek, Thomas R.
共 7 条
Predoctoral Training in Translational Immunology
-
批准号:10493792
-
项目类别:
-
资助金额:$10.56万
-
财政年份:2022
-
负责人:Thomas R Malek
-
依托单位:
Predoctoral Training in Translational Immunology
-
批准号:10684090
-
项目类别:
-
资助金额:$16.14万
-
财政年份:2022
-
负责人:Thomas R Malek
-
依托单位:
Bi-functional fusion proteins to regulate autoimmunity
-
批准号:10373388
-
项目类别:
-
资助金额:$23.03万
-
财政年份:2021
-
负责人:Thomas R Malek
-
依托单位:
Bi-functional fusion proteins to regulate autoimmunity
-
批准号:10528479
-
项目类别:
-
资助金额:$19.19万
-
财政年份:2021
-
负责人:Thomas R Malek
-
依托单位:
IL-2R-dependent mechanisms in regulation of Treg homeostasis and autoimmunity
-
批准号:10304194
-
项目类别:
-
资助金额:$61.94万
-
财政年份:2019
-
负责人:Thomas R Malek
-
依托单位:
Low-dose IL-2 in Established T1D
-
批准号:9761962
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:Thomas R Malek
-
依托单位:
Low dose IL-2 and human regulatory T cells
-
批准号:10061539
-
项目类别:
-
资助金额:$60.33万
-
财政年份:2017
-
负责人:Thomas R Malek
-
依托单位:
Low dose IL-2 and human regulatory T cells
-
批准号:10308487
-
项目类别:
-
资助金额:$60.33万
-
财政年份:2017
-
负责人:Thomas R Malek
-
依托单位:
Low-dose IL-2 in Established T1D
-
批准号:9544827
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:Thomas R Malek
-
依托单位:
A novel IL-2 biologic and tumor immunity
-
批准号:9185950
-
项目类别:
-
资助金额:$20.03万
-
财政年份:2015
-
负责人:Thomas R Malek
-
依托单位:
IL-2-dependent mechanisms in T1D
-
批准号:8439428
-
项目类别:
-
资助金额:$33.28万
-
财政年份:2012
-
负责人:Thomas R Malek
-
依托单位:
IL-2-dependent mechanisms in T1D
-
批准号:8554761
-
项目类别:
-
资助金额:$32.11万
-
财政年份:2012
-
负责人:Thomas R Malek
-
依托单位:
The immunobiology of CD4+ CD25+ T regulatory cells
-
批准号:8384876
-
项目类别:
-
资助金额:$35.96万
-
财政年份:2010
-
负责人:Thomas R Malek
-
依托单位:
The immunobiology of CD4+ CD25+ T regulatory cells
-
批准号:8580546
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2010
-
负责人:Thomas R Malek
-
依托单位:
The immunobiology of CD4+ CD25+ T regulatory cells
-
批准号:8039479
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2010
-
负责人:Thomas R Malek
-
依托单位:
The immunobiology of CD4+ CD25+ T regulatory cells
-
批准号:8204397
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2010
-
负责人:Thomas R Malek
-
依托单位:
T cell immunity and cytokine receptor signaling
-
批准号:7907205
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2009
-
负责人:Thomas R Malek
-
依托单位:
Memory T Cells in Tumpr Immunity
-
批准号:7226410
-
项目类别:
-
资助金额:$23.42万
-
财政年份:2006
-
负责人:Thomas R Malek
-
依托单位:
Immunobiology of CD4+CD25+ T regulatory cells
-
批准号:6823665
-
项目类别:
-
资助金额:$34.09万
-
财政年份:2004
-
负责人:Thomas R Malek
-
依托单位:
Immunobiology of CD4+CD25+ T regulatory cells
-
批准号:7224940
-
项目类别:
-
资助金额:$32.32万
-
财政年份:2004
-
负责人:Thomas R Malek
-
依托单位:
海外基金